ONK THERAPEUTICS LIMITED - Key Persons

Job Titles:

• Chairman
• Director
• Chief Financial Officer ( CFO ) of Prime Medicine
• Independent Non - Executive Director & Chairman of ONK Therapeutics Board

Allan is an independent Non-Executive Director & Chairman of ONK Therapeutics board, he also serves as Chair of our Audit Committee. He is an experienced biotechnology chief financial officer and investor who has been active in the industry since 2001. Allan is Chief Financial Officer (CFO) of Prime Medicine. Previously, Allan was CFO of Foghorn Therapeutics. Prior to that, he was an investor for almost 15 years, managing various healthcare portfolios focused on biotechnology and pharmaceutical companies at Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital Advisors, Trivium Capital and Alexandra Investment Management. He started his career at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Allan received his MD from the University of Toronto, and his Bachelor of Science in statistical sciences from the University of Western Ontario. Allan is an independent Non-Executive Director & Chairman of ONK Therapeutics board. He is an experienced biotechnology chief financial officer and investor who has been active in the industry since 2001.

Job Titles:

• Director
• Founder

Anthony Killarney is a Founder of ONK Therapeutics and now serves as a Director, having been Chairman of the Board until January 2021.

Job Titles:

• Chief Scientific Officer

Bruce McCreedy has over three decades of experience in the development and approval of drugs for the treatment of cancer, autoimmune disorders, and infectious diseases. He joined ONK Therapeutics as CSO in December 2022. Previously, Bruce was Chief Science Officer at Myeloid Therapeutics, a clinical stage immunology company. He has also served as Senior Vice President Cell Therapy and Immuno-Oncology Research at Precision BioSciences, Inc.where he oversaw the development of a portfolio of gene edited allogeneic CAR T therapies. Previous industry positions held by Bruce include Executive Vice President and Chief Development Officer for Neximmune, Inc., President and CEO of Fulcrum Pharma Developments, Inc. and Vice President of Clinical Virology and Diagnostics for Triangle Pharmaceuticals, Inc. (now Gilead Sciences). Bruce obtained a PhD in Microbiology and Immunology from the School of Medicine, Wake Forest University, North Carolina.

Job Titles:

• Chief Executive Officer
• Director
• Senior Global Biopharma Executive

Chris Nowers is a senior global biopharma executive with significant experience in the areas of cell therapy and immuno-oncology. He joined ONK Therapeutics as CEO in October 2020. Prior to joining ONK Therapeutics Chris was CEO of Cell Medica, an early stage cell therapy company exploring CAR therapy based on natural killer T cells. Prior to that, he was Head of Europe at Kite Pharma (acquired by Gilead), where he was responsible for building the European organization from the ground up and full European commercialization of the CAR-T therapy axicabtagene ciloleucel.

Job Titles:

• Accountant
• Director
• Founding Director and Experienced Biopharmaceutical Executive
• Prof Jeffrey Miller

Eunan is an experienced biopharmaceutical executive. Most recently he co-founded Adapt Pharma, a leader in opioid overdose treatment, where he served as its Chief Operating Officer until its sale to Emergent BioSolutions. Previously he co-founded Azur Pharma, a CNS and Women's Health Pharmaceutical business, and served as its President until it merged with Jazz Pharmaceuticals. He subsequently led strategy and corporate development at Jazz. Earlier in his career, Eunan was Vice President of business development at King Pharmaceuticals (acquired by Pfizer) and Strategy at Elan Corporation. Eunan is an accountant by profession and trained at KPMG. His board memberships include AixThera, ALSHC and Avectas. He received a Bachelor of International Commerce and French from University College Dublin, Ireland. Eunan Maguire is founding director and experienced biopharmaceutical executive. Most recently he co-founded Adapt Pharma, a leader in opioid overdose treatment, where he served as its Chief Operating Officer until its sale to Emergent BioSolutions.

Job Titles:

• Member of the Board of Directors

Isaac Manke is an experienced life sciences venture capitalist and represents Acorn BioVentures on the board. He joined Acorn BioVentures as a General Partner in 2020. Previously, he was a General Partner at New Leaf Venture Partners, where he invested across private and public biotechnology companies for 11 years. Prior to his venture capital career, he was an analyst and held roles that included Associate Equity Analyst, in the Global Biotechnology Equity Research group at Sanford C. Bernstein and in the Biotechnology Equity Research group at Deutsche Bank. Previously, he was a Senior Analyst at Health Advances, a biopharmaceutical and medical device strategy consulting firm. In his earlier career as a research scientist at the Massachusetts Institute of Technology (MIT) Isaac's discoveries led to several publications in top journals, including Science and Cell, and were selected by Science as one of the "2003: Signaling Breakthroughs of the Year". These discoveries also resulted in four issued patents.

Job Titles:

• Professor of Medicine at the University of Minnesota

Jeffrey S. Miller, is currently a Professor of Medicine at the University of Minnesota, Division of Hematology, Oncology and Transplantation. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Centerand Roger L. and Lynn C. Headrick Chair in Cancer Therapeutics. Dr Miller has more than 20 years of experience studying the biology of natural killer (NK) cells and other immune effector cells and their use in clinical immunotherapy with over 200 peer-reviewed publications. After completing a post-doctoral fellowship in Hematology, Oncology and Transplantation at the University of Minnesota, he joined the faculty in 1991. Previously, he completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for the Journal of Immunology and BBMT, and is a reviewer for a number of journals and NIH grants. Dr. Miller was the recipient of the National Cancer Institute Outstanding Investigator Award for 2015-2022. Dr Miller received a BSc degree from Northwestern University in Evanston, Illinois, US and received his MD from Northwestern University School of Medicine.

Job Titles:

• Founding Director

Malcolm K Brenner is the Founding Director, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital and the Fayez Sarofim Distinguished Service Professor at BCM. Over the past 30 years, Dr Brenner has devoted his career as a physician-scientist to the field of stem cell transplantation through the therapeutic use of T cell immunologic approaches and genetic engineering strategies, particularly in the treatment of cancer. He served as Editor-in-Chief of Molecular Therapy and as former President of the American Society for Gene and Cell Therapy (ASGCT) and of the International Society for Cell Therapy. Previously he was Head of the Cell and Gene Therapy Program at St Jude Children's Research Hospital, where his group performed the first human gene transfer studies outside of the NIH and the first anywhere to use marrow stem cells as the target. Dr Brenner has earned widespread recognition for his scientific achievements and leadership in the field, including the ASGCT Outstanding Achievement Award, Human Gene Therapy's Pioneer Award, the American Society of Hematology Mentor Award and the European Society of Gene and Cell Therapy Outstanding Achievement award. For his contributions to the field, Dr. Brenner has been elected a member of the American Association of Physicians and of the National Academy of Medicine Dr Brenner obtained his medical degrees and his PhD from the University of Cambridge, England.

Job Titles:

• Director
• Founder
• Clinician Scientist
• Member of the American Society of Hematology
• Patent Attorney
• Patent Attorney & Director
• Prof Philippe Moreau

Michael O'Dwyer is an experienced Clinician Scientist with a strong track record in clinical and translational research in blood cancers and has been involved in the clinical drug development of many ground-breaking treatments for Leukemia and Multiple Myeloma. He is a Professor of Hematology responsible for clinical and translational research in blood cancers at the University of Galway, Ireland, and Founder, Director and Advisor to ONK Therapeutics. From 2020-2022 Michael was the company's CSO, where he played a key role in the development of ONK's optimally engineered NK cell therapy platform. In recent years his main research focus has been on Multiple Myeloma where he is studying the immune microenvironment, the impact of glycosylation on cell trafficking and immune evasion and the genetic modification of Natural Killer (NK) cells to enable cell therapy for cancer. He has over 100 peer reviewed publications and is listed as an inventor on more than 10 patents. Michael is a member of the American Society of Hematology (ASH), the European Hematology Association (EHA) Scientific Working Party on Immunotherapy of Hematologic Malignancies and the International Myeloma Working Group (IMWG). He is also on the Scientific Advisory Board of Carrick Therapeutics. Earlier in his career Michael was Assistant Professor at Oregon Health & Sciences University (OHSU), Portland, USA, where he worked on the development of imatinib. Michael has an MD degree from NUI Galway (now University of Galway, Ireland) and undertook training in Hematology in Ireland followed by a Fellowship in Hematology and Medical Oncology at OHSU. George Schlich is a UK and European Patent Attorney, a founding director of ONK Therapeutics and has been responsible from the start for the IP portfolio. Michael O'Dwyer is an experienced Clinician Scientist with a strong track record in clinical and translational research in blood cancers and has been involved in the clinical drug development of many ground-breaking treatments for Leukemia and Multiple Myeloma. He is a Professor of Hematology at the University of Galway, Ireland, is a Founder of ONK Therapeutics and now serves as a Director.

Job Titles:

• Head
• Prof Jeffrey Miller
• Professor

Philippe Moreau is a Professor of Clinical Hematology and Head of the Translational Research Program in Hematology and Oncology, at the University Hospital of Nantes, France. He has over 20 years' experience in clinical hematology and has led many pivotal clinical studies. including with cell therapies. His interests are focused on multiple myeloma (MM) and its treatment with high-dose therapy and novel agents, including cell therapies. Professor Moreau has been the Chairman of the Intergroupe Francophone du Myélome (IFM) since 2020 and Vice-President of the International Myeloma Society (IMS) since 2019. He has been a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. Professor Moreau has served as the Principal Investigator for many international randomized phase 3 clinical trials evaluating proteasome inhibitors, Immunomodulatory drugs (IMiDs) or CD38 antibodies. He participated in the study of Idecabtagene Vicleucel (Abecma), that received FDA approval in March 2021 as the first genetically modified autologous chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed and refractory MM. He has authored or coauthored more than 400 peer-reviewed articles that have appeared in high impact factor journals including, the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet, The Lancet Oncology, and Blood. In 2018 Professor Moreau received the Robert A. Kyle lifetime achievement award. Professor Moreau obtained his medical degree from the University of Reims, France.